Maternal and perinatal outcomes in pregnant women with rheumatic diseases treated with biosimilar TNF inhibitors

Ana Teodósio Chícharo^{1

2}, Ana R Lopes^{1

3}, Sofia Barreira^{1

3}, Luísa Pinto⁴, Ana R Cruz-Machado^{1

3}, Susana Capela^{1

3}

Affiliations

¹ Rheumatology and Metabolic Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Center, European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET) and RITA Full Member, Lisbon, Portugal.
² Rheumatology Department, Centro Hospitalar Universitário do Algarve, Hospital de Faro, Faro, Portugal.
³ Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.
⁴ Department of Obstetrics, Gynecology and Reproductive Medicine, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.

Ana Teodósio Chícharo et al. Rheumatol Adv Pract. 2024.

. 2024 Mar 19;8(2):rkae044.

doi: 10.1093/rap/rkae044. eCollection 2024.

Ana Teodósio Chícharo^{1

2}, Ana R Lopes^{1

3}, Sofia Barreira^{1

3}, Luísa Pinto⁴, Ana R Cruz-Machado^{1

3}, Susana Capela^{1

3}

¹ Rheumatology and Metabolic Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Center, European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET) and RITA Full Member, Lisbon, Portugal.
² Rheumatology Department, Centro Hospitalar Universitário do Algarve, Hospital de Faro, Faro, Portugal.
³ Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.
⁴ Department of Obstetrics, Gynecology and Reproductive Medicine, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.

No abstract available

Cited by

Use of Biosimilars to Infliximab During Pregnancy in Women With Inflammatory Bowel Disease: Results From the Pregnancy in Inflammatory Bowel Disease and Neonatal Outcomes Study.
Long MD, Kane S, Beaulieu D, Abraham B, Zhang X, Mahadevan U. Long MD, et al. Clin Transl Gastroenterol. 2024 Dec 1;15(12):e00795. doi: 10.14309/ctg.0000000000000795. Clin Transl Gastroenterol. 2024. PMID: 39665589 Free PMC article.

1. De Felice KM, Kane S.. Safety of anti-TNF agents in pregnancy. J Allergy Clin Immunol 2021;148:661–7. - PubMed
1. Luu M, Benzenine E, Doret M. et al. Continuous anti-TNFa use throughout pregnancy: possible complications for the mother but not for the fetus. A retrospective cohort on the French National Health Insurance Database (EVASION). Am J Gastroenterol 2018;113:1669–77. - PubMed
1. Götestam Skorpen C, Hoeltzenbein M, Tincani A. et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016;75:795–810. - PubMed
1. Sammaritano LR, Bermas BL, Chakravarty EE. et al. 2020 American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Care Res (Hoboken) 2020;72:461–88. - PubMed
1. Russell MD, Dey M, Flint J. et al.; BSR Standards, Audit and Guidelines Working Group. British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford) 2023;62:e48–88. - PMC - PubMed